Biomarin Pharmaceutical (BMRN) Free Cash Flow (QoQ) (2009 - 2026)
Biomarin Pharmaceutical (BMRN) Free Cash Flow (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn |
| 10 | Biomarin Pharmaceutical | 11.70 Bn | 9.48 Bn | 571.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 238.97% |
| Dec 31, 2025 | -81.58% |
| Sep 30, 2025 | 69.66% |
| Jun 30, 2025 | 19.61% |
| Mar 31, 2025 | -5.10% |
| Dec 31, 2024 | -18.19% |
| Sep 30, 2024 | 108.36% |
| Jun 30, 2024 | 366.93% |
| Mar 31, 2024 | -67.45% |
| Dec 31, 2023 | -12.76% |
| Sep 30, 2023 | -17.34% |
| Jun 30, 2023 | 190.36% |
| Mar 31, 2023 | 22.11% |
| Dec 31, 2022 | -178.30% |
| Sep 30, 2022 | 71.26% |
| Jun 30, 2022 | 226.86% |
| Mar 31, 2022 | -1,586.74% |
| Dec 31, 2021 | -94.82% |
| Sep 30, 2021 | -11.31% |
| Jun 30, 2021 | 23.42% |